Andrew specializes in commercial health insurance pricing and filing and value-based contracting. His areas of expertise include:
Preparing commercial state and federal rate filings for both ACA and non-ACA products, including individual, small group, and large group
Providing actuarial support to health plans, including benchmarking, pricing, benefits compliance, reserving, and financial projections
Developing and evaluating risk contract frameworks and parameters between payers and providers
Analyzing healthcare utilization, costs, and trends for various clients using large commercial, Medicare, and Medicaid claims databases
Modeling various alternative payment risk-sharing strategies for payers, providers, and pharmaceutical manufacturers
Prior to joining Milliman, Andrew worked for a large consulting firm where he performed valuations for defined benefit pension plans, consulted on de-risking strategies for pension plans, and performed asset-liability studies to determine the optimal level of risk that pension plans should incorporate in their investments.
Publications and Presentations
Andrew is a frequent speaker at the Milliman Health Forum. He has also published a number of papers and articles on various healthcare topics.
Professional Designations
Fellow, Society of Actuaries
Member, American Academy of Actuaries
Education
BA, Economics and Finance, Washington University, St. Louis
20 October 2020 - by Andrew Bochner, Jennifer Carioto, Luis Maldonado
How will COVID-19 affect a health plan’s medical loss ratio requirements in general and what are specific considerations for the commercial, Medicare Advantage, and Medicaid markets in 2020 and going forward?
29 June 2020 - by Dane Hansen, Andrew Bochner, Emily DeAngelis
This paper examines the reported impact of COVID-19 on preliminary rate filings among six states and D.C. that have been publicly released as of June 15, 2020.
27 March 2018 - by Andrew Bochner, Gabriela Dieguez, Bruce S. Pyenson
This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.
22 August 2016 - by Warner Huh, Andrew Bochner, Kate Fitch
This paper analyzes commercial payer differences in the average costs and readmission rates between inpatient open hysterectomies and three types of outpatient hysterectomies: laparoscopic, laparoscopic assisted, and vaginal.
06 August 2016 - by Andrew Bochner, Tyler Engel, Kate Fitch
This study analyzes the difference in payer costs between minimally invasive surgery and open surgery in a commercial population for four commonly performed elective surgical procedures.
24 September 2015 - by Andrew Bochner, Ryan Cannon, Bruce S. Pyenson
HCV is the leading cause of both liver-related deaths and liver transplants in the United States. The high cost of new antiviral medicines has sparked debate over the cost of treating HCV, and some payers are seeking ways to minimize their spending on these medicines.
